|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/29/22 CollPlant Biotechnologies Ltd. 6-K 6/29/22 2:60K EdgarAgents LLC/FA |
Document/Exhibit Description Pages Size 1: 6-K Report of Foreign Private Issuer HTML 10K 2: EX-99.1 Press Release, Dated June 29, 2022 HTML 15K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2022
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
The first paragraph and “Forward Looking Statements” of the press release attached to this Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479 and 333-263842) and Form F-3 (File No. 333-228054 and 333-238731), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
C:
On June 29, 2022, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study.” A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit
| Exhibit | ||
| 99.1 | Press Release, dated June 29, 2022 |
C:
C: 1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| COLLPLANT BIOTECHNOLOGIES LTD. | |||
| Date: June 29, 2022 | By: | /s/ Eran Rotem | |
| Name: | Eran Rotem | ||
| Title: | Deputy CEO and Chief Financial Officer | ||
2
| This ‘6-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 6/29/22 | None on these Dates | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/30/22 CollPlant Biotechnologies Ltd. F-3 6:415K EdgarAgents LLC/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/22 CollPlant Biotechnologies Ltd. S-8 3/25/22 4:81K EdgarAgents LLC/FA 8/28/20 CollPlant Biotechnologies Ltd. S-8 8/28/20 3:116K EdgarAgents LLC/FA 5/27/20 CollPlant Biotechnologies Ltd. F-3 3:479K EdgarAgents LLC/FA 4/08/19 CollPlant Biotechnologies Ltd. F-3/A 3:425K EdgarAgents LLC/FA 1/08/19 CollPlant Biotechnologies Ltd. S-8 1/08/19 3:101K EdgarAgents LLC/FA |